{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:44:48Z","timestamp":1791902688550,"version":"4.3.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014475","name":"Pfizer Health Research Foundation","doi-asserted-by":"publisher","award":["94667969"],"award-info":[{"award-number":["94667969"]}],"id":[{"id":"10.13039\/100014475","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jaad.2025.07.008","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T18:36:56Z","timestamp":1752604616000},"page":"1236-1242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world efficacy of ritlecitinib in treating alopecia areata across various anatomical sites: Potential rapid response predictors"],"prefix":"10.1016","volume":"93","author":[{"given":"Jundong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2025.07.008_bib1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia areata: an update on etiopathogenesis, diagnosis, and management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2025.07.008_bib2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jaad.2017.10.048","article-title":"Objective outcome measures: collecting meaningful data on alopecia areata","volume":"79","author":"Olsen","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"2 Pt 1","key":"10.1016\/j.jaad.2025.07.008_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0190-9622(99)70195-7","article-title":"Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation","volume":"40","author":"Olsen","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.07.008_bib4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","article-title":"Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort","volume":"86","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"10387","key":"10.1016\/j.jaad.2025.07.008_bib5","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2025.07.008_bib6","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/ced\/llae548","article-title":"Efficacy and safety of switching from baricitinib to ritlecitinib in severe alopecia areata","volume":"50","author":"Chen","year":"2025","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.07.008_bib7","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaad.2025.01.090","article-title":"Effectiveness and tolerability of ritlecitinib in children with alopecia areata: a case series","volume":"92","author":"Huang","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.07.008_bib8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40257-020-00545-9","article-title":"Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata","volume":"21","author":"Wyrwich","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.07.008_bib9","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.18883","article-title":"The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials","volume":"183","author":"Wyrwich","year":"2020","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.07.008_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/13543784.2024.2348062","article-title":"Novel investigational drugs for alopecia areata and future perspectives","volume":"33","author":"Chim","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jaad.2025.07.008_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.950450","article-title":"The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies","volume":"13","author":"Yan","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jaad.2025.07.008_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.07.008_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/bjd\/ljae365","volume":"192","author":"Piliang","year":"2025","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.07.008_bib14","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/jdv.20526","article-title":"Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: results from the ALLEGRO-LT phase 3, open-label study","volume":"39","author":"Tziotzios","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2025.07.008_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","article-title":"Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program","volume":"25","author":"King","year":"2024","journal-title":"Am J Clin Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225024600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225024600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:01:45Z","timestamp":1763046105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225024600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0190962225024600"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.07.008","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy of ritlecitinib in treating alopecia areata across various anatomical sites: Potential rapid response predictors","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}